Literature DB >> 16687047

The B cell response in multiple sclerosis.

Gregory P Owens1, Jeffrey L Bennett, Donald H Gilden, Mark P Burgoon.   

Abstract

Multiple sclerosis (MS) plaques and CSF contain increased amounts of intrathecally synthesized IgG, manifest as oligoclonal bands (OCBs) after protein electrophoresis. OCBs are not unique to MS and are also produced in infectious diseases of the CNS, in which the oligoclonal IgG has been shown to be antibody directed against the disease-causing agent. Thus, analysis of antibody specificity may identify the causative agent/antigen in MS. This review discusses recent studies that have analyzed the phenotypes of B cells in MS which infiltrate the CNS and the molecular features of their antigen-binding regions. Together with histologic studies showing the presence of ectopic lymphoid follicles in the meninges of some MS patients, this data supports the notion of a targeted and compartmentalized humoral response in MS.

Entities:  

Mesh:

Year:  2006        PMID: 16687047     DOI: 10.1179/016164106X98099

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  27 in total

1.  CXCR3-dependent plasma blast migration to the central nervous system during viral encephalomyelitis.

Authors:  Cristina P Marques; Parul Kapil; David R Hinton; Claudia Hindinger; Stephen L Nutt; Richard M Ransohoff; Timothy W Phares; Stephen A Stohlman; Cornelia C Bergmann
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

2.  The spleen is the major source of antidonor antibody-secreting cells in murine heart allograft recipients.

Authors:  A Sicard; T W Phares; H Yu; R Fan; W M Baldwin; R L Fairchild; A Valujskikh
Journal:  Am J Transplant       Date:  2012-03-15       Impact factor: 8.086

3.  Atacicept: targeting B cells in multiple sclerosis.

Authors:  Hans-Peter Hartung; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

4.  A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosis.

Authors:  A J Ligocki; L Lovato; D Xiang; P Guidry; R H Scheuermann; S N Willis; S Almendinger; M K Racke; E M Frohman; D A Hafler; K C O'Connor; N L Monson
Journal:  J Neuroimmunol       Date:  2010-07-23       Impact factor: 3.478

Review 5.  Autophagy, inflammation and neurodegenerative disease.

Authors:  Mehrdad Alirezaei; Christopher C Kemball; J Lindsay Whitton
Journal:  Eur J Neurosci       Date:  2010-12-07       Impact factor: 3.386

Review 6.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

Review 7.  Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.

Authors:  J Nicholas Brenton; Brenda L Banwell
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 8.  Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale.

Authors:  Dimitrios Karussis; Panayiota Petrou
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

9.  Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.

Authors:  Elizabeth M Cameron; Sade Spencer; Jonathan Lazarini; Christopher T Harp; E Sally Ward; Mark Burgoon; Gregory P Owens; Michael K Racke; Jeffrey L Bennett; Elliot M Frohman; Nancy L Monson
Journal:  J Neuroimmunol       Date:  2009-07-24       Impact factor: 3.478

10.  A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk.

Authors:  Cecilia Ahlgren; Kjell Torén; Anders Odén; Oluf Andersen
Journal:  Eur J Epidemiol       Date:  2009-07-26       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.